Sign in
Active, not recruitingNo phase

MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms

Key facts

Who runs it
CooperVision, Inc.
Where
Athens, Beaumont, Bellevue, Birmingham, Bloomington, Boston, Chesapeake, Chicago, Columbus, Downers Grove, Edina, Fullerton, Glenview, Granville, Houston, Kansas City, Katy, La Mesa, Memphis, Miamisburg, Ocoee, Ogden, Pittsburg, Plano, Powell, Santa Ana, Schaumburg, Tamarac, and Tampa, United StatesSee the 30 sites
Trial code
Status
Active, not recruiting
People taking part
900 people, planned
Started
25 Jun 2022
Expected to end
30 Jun 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • MiSight 1 Day
  • Proclear 1 day
Record updated
8 July 2026

Who can take part

Age
8 years to 12 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (23)Hide the full registry criteria

Who can take part

  • Informed Consent and Assent have been completed
  • Be between 8 and 12 years of age inclusive at the time of enrollment
  • Manifest Refraction - Spherical Equivalent Refractive Error (SERE) at baseline between -0.75 D and -4.00 D inclusive (at the corneal plane) in each eye
  • Best-corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye
  • Anisometropia: ≤ 1.50D SERE
  • Astigmatism: ≤ 0.75 D
  • Free of ocular disease or abnormalities (including any corneal scar)
  • Currently have good general health
  • Agree to accept the lens as assigned by the randomization
  • Be capable of comprehending the nature of the study and be willing and able to adhere to the instructions set forth in this protocol
  • Ability to comply with study procedures, including high and low (sub-study only) contrast high and low (sub-study only) lighting visual acuity, axial length, and cycloplegic auto-refraction measurements taken for both eyes
  • Able to maintain the visit schedule
  • Willingness to participate in the trial for 4 years
  • Interested in wearing contact lenses for approximately 10 hours per day and 6 days per week
  • Possesses, or obtains prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses

Who cannot take part

  • Current or prior use of any pharmaceuticals or other methods for control of myopia, such as bifocals, progressive addition lenses, orthokeratology, atropine, pirenzepine or any other myopia control treatment
  • Use of any systemic or topical ocular medications or over-the-counter artificial tears which might interfere with contact lens wear, pupil size, accommodation or refractive state, or require the lenses to be removed during the day
  • Previously worn or currently wears rigid gas permeable contact lenses, including orthokeratology lenses
  • Has any of the following specific contraindications to MiSight 1 Day lenses at Baseline Visit:; Acute and subacute inflammation or infection of the anterior chamber of the eye; Any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids; Severe insufficiency of lacrimal secretion (dry eyes); Corneal hypoesthesia (reduced corneal sensitivity), if not aphakic; Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses; Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses or use of contact lens solutions; Any active corneal infection (bacterial, fungal, or viral); If eyes are red or irritated; The patient is unable to follow lens handling and wear regimen or unable to obtain assistance to do so
  • Has history of:; Corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections; Giant papillary conjunctivitis; Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by wearing contact lenses; A known allergy to fluorescein, benoxinate, proparacaine or tropicamide; Corneal hypoesthesia (reduced corneal sensitivity)
  • Any systemic disease that may affect the eye or be exaggerated by wearing contact lenses
  • Keratoconus or an irregular cornea
  • Strabismus or amblyopia

Where in United States

  • Athens Eye CareAthens, United States
  • Texas State OpticalBeaumont, United States
  • Factoria Eye ClinicBellevue, United States
  • University of Alabama School of OptometryBirmingham, United States
  • Clinical Optics Research Lab at IU School of OptometryBloomington, United States
  • New England College of OptometryBoston, United States
  • Virginia Pediatric Eye CareChesapeake, United States
  • Illinois College of OptometryChicago, United States
  • SoLo Eye Care & Eyewear GalleryChicago, United States
  • Ohio State UniversityColumbus, United States
  • Chicago College of OptometryDowners Grove, United States
  • Cornea and Contact Lens InstituteEdina, United States
  • Marshall B. Ketchum University Southern California College of OptometryFullerton, United States
  • Carillon Vision CareGlenview, United States
  • ProCare Vision Center, Inc.Granville, United States
  • University of Houston College of OptometryHouston, United States
  • Vision Source EyeCareKansas City, United States
  • Vision One EyecareKaty, United States
  • Vision Solutions Optometry IncLa Mesa, United States
  • Southern College of OptometryMemphis, United States
  • Miamisburg Vision CareMiamisburg, United States
  • Coan Eye Care and Optical BoutiqueOcoee, United States
  • Utah Eye CentersOgden, United States
  • Kannarr Eye CarePittsburg, United States
  • Lone Star VisionPlano, United States
  • Eye Care ProfessionalsPowell, United States
  • Paje OptometricSanta Ana, United States
  • Brain Vision InstituteSchaumburg, United States
  • West Broward Eyecare AssociatesTamarac, United States
  • Bright Eyes Family Vision CareTampa, United States

About the trial

What the trial wants to find out

The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year post-treatment.

The 2 groups in the trial

  • MiSight 1 dayTreatment being tested
  • Proclear 1 dayExisting treatment, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
8 July 2026